International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
2017 · European Respiratory Journal · 1,313 citations
https://doi.org/10.1183/13993003.00582-2017
R
Richard G. Wunderink
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
593
Papers
47.3K
Citations
98
h-index
295
i10-index
Richard G. Wunderink is an academic researcher from Northwestern University. The author has contributed to research in topics: Pneumonia and Respiratory Infections & Nosocomial Infections in ICU & Respiratory viral infections research. The author has an h-index of 98, co-authored 505 publications.
ORCID: 0000-0002-8527-4195Papers by this author
worksInternational Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
2019 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 880 citations
https://doi.org/10.1002/phar.2209
Pneumonia
2021 · Nature Reviews Disease Primers · 767 citations
https://doi.org/10.1038/s41572-021-00259-0
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
2020 · The Lancet Infectious Diseases · 732 citations
https://doi.org/10.1016/s1473-3099(20)30796-9
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
2020 · The Lancet Infectious Diseases · 432 citations
https://doi.org/10.1016/s1473-3099(20)30731-3
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
2018 · Infectious Diseases and Therapy · 418 citations
https://doi.org/10.1007/s40121-018-0214-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat